The Emergence of Psilocybin in Psychiatry and Neuroscience

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 555 - 555

Published: April 9, 2025

Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, safety profile. Emerging evidence supports efficacy conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, limited population diversity trials. Advances biosynthetic production optimized psychotherapeutic integration are necessary to ensure scalability accessibility. Future should focus long-term safety, dosing precision, neurobiological mechanisms refine therapeutic applications. provides critical foundation advancing evidence-based of psilocybin.

Language: Английский

Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice

Neuroscience, Journal Year: 2024, Volume and Issue: 559, P. 156 - 165

Published: Sept. 3, 2024

Language: Английский